DK3142655T3 - Sammensætninger og fremgangsmåder til behandling af hjertefibrose med ifetroban - Google Patents
Sammensætninger og fremgangsmåder til behandling af hjertefibrose med ifetroban Download PDFInfo
- Publication number
- DK3142655T3 DK3142655T3 DK15792047.1T DK15792047T DK3142655T3 DK 3142655 T3 DK3142655 T3 DK 3142655T3 DK 15792047 T DK15792047 T DK 15792047T DK 3142655 T3 DK3142655 T3 DK 3142655T3
- Authority
- DK
- Denmark
- Prior art keywords
- ifetroban
- compositions
- methods
- cardiac fibrosis
- treating cardiac
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461994436P | 2014-05-16 | 2014-05-16 | |
| US201462060198P | 2014-10-06 | 2014-10-06 | |
| US201462078649P | 2014-11-12 | 2014-11-12 | |
| US201562118896P | 2015-02-20 | 2015-02-20 | |
| PCT/US2015/031395 WO2015176060A1 (en) | 2014-05-16 | 2015-05-18 | Compositions and methods of treating cardiac fibrosis with ifetroban |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3142655T3 true DK3142655T3 (da) | 2021-02-01 |
Family
ID=54480852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15792047.1T DK3142655T3 (da) | 2014-05-16 | 2015-05-18 | Sammensætninger og fremgangsmåder til behandling af hjertefibrose med ifetroban |
Country Status (9)
| Country | Link |
|---|---|
| US (6) | US9693998B2 (da) |
| EP (2) | EP3804717A1 (da) |
| JP (1) | JP6273072B2 (da) |
| CN (2) | CN111728970A (da) |
| AU (2) | AU2015258805B2 (da) |
| DK (1) | DK3142655T3 (da) |
| ES (1) | ES2848348T3 (da) |
| WO (1) | WO2015176060A1 (da) |
| ZA (1) | ZA201607878B (da) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111728970A (zh) | 2014-05-16 | 2020-10-02 | 坎伯兰医药品股份有限公司 | 用伊非曲班治疗心脏纤维化的组合物和方法 |
| WO2016134257A1 (en) | 2015-02-19 | 2016-08-25 | Lixter Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders |
| EP3316882A4 (en) | 2015-06-30 | 2019-02-20 | Cumberland Pharmaceuticals Inc. | ANTAGONISTS OF THROMBOXANE RECEPTOR IN MREA / ASTHMA |
| CA3020185A1 (en) * | 2016-04-27 | 2017-11-02 | Cumberland Pharmaceuticals, Inc. | Ifetroban treatment for systemic sclerosis |
| CN115624549A (zh) * | 2016-05-11 | 2023-01-20 | 坎伯兰医药品股份有限公司 | 用血栓烷-a2受体拮抗剂治疗肌营养不良的组合物和方法 |
| WO2018124236A1 (ja) * | 2016-12-27 | 2018-07-05 | 国立大学法人大阪大学 | 難治性心疾患治療用医薬組成物 |
| KR20220161394A (ko) * | 2020-03-31 | 2022-12-06 | 마틴 오글트리 | Covid-19의 치료를 위한 방법 및 트롬복산 a2 수용체 길항제의 약학 조성물 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2809377A1 (de) | 1978-03-04 | 1979-09-13 | Boehringer Mannheim Gmbh | Phenoxyalkylcarbonsaeure-derivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel |
| DE3000377A1 (de) | 1980-01-07 | 1981-07-09 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue sulfonamide, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel |
| US4537981A (en) | 1981-11-09 | 1985-08-27 | E. R. Squibb & Sons, Inc. | 7-Oxabicycloheptane and 7-oxabicycloheptene compounds |
| US4416896A (en) | 1982-05-17 | 1983-11-22 | E. R. Squibb & Sons, Inc. | 7-Oxabicyclopheptane substituted amino prostaglandin analogs useful in the treatment of thrombolytic disease |
| US4663336A (en) | 1985-07-01 | 1987-05-05 | E. R. Squibb & Sons, Inc. | 7-oxabicycloheptane substituted diamide and its congener prostaglandin analogs useful in the treatment of thrombotic disease |
| US4752616A (en) | 1987-06-29 | 1988-06-21 | E. R. Squibb & Sons, Inc. | Arylthioalkylphenyl carboxylic acids, compositions containing same and method of use |
| US5066480A (en) | 1988-04-11 | 1991-11-19 | E. R. Squibb & Sons, Inc. | Method of preventing or reducing adverse reactions to protamine using a thromboxane a2 receptor antagonist |
| US4839384A (en) | 1988-10-07 | 1989-06-13 | E. R. Squibb & Sons, Inc. | Method of inhibiting onset of or treating migraine headache using a thromboxane A2 receptor antagonist |
| US5100889A (en) | 1989-04-03 | 1992-03-31 | E. R. Squibb & Sons, Inc. | 7-oxabicycloheptyl substituted heterocyclic amide or ester prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease |
| JPH02273625A (ja) | 1989-04-14 | 1990-11-08 | Takeda Chem Ind Ltd | 高エンドセリン症予防・治療剤 |
| US4977174A (en) | 1989-06-12 | 1990-12-11 | E. R. Squibb & Sons, Inc. | 7-oxabicycloheptane imidazole prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease |
| US5128359A (en) | 1990-02-16 | 1992-07-07 | Laboratoires Upsa | Benzimidazole and azabenzimidazole derivatives which are thromboxane receptor antagonists, their methods of preparation |
| ZA911453B (en) | 1990-03-19 | 1991-11-27 | Squibb & Sons Inc | Method of protecting against and/or treating ulcerative gastrointestinal conditions using a thromoboxane,a2 receptor antagonist and combination useful in preventing and/or treating ulcers and/or inflammation |
| US5529992A (en) * | 1992-04-21 | 1996-06-25 | Curators Of The University Of Missouri | Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors |
| US5399725A (en) | 1993-05-27 | 1995-03-21 | Bristol-Myers Squibb Co. | 7-oxabicycloheptane carboxylic acid prostaglandin analog intermediates useful in the preparation of anti-thrombotic and anti-vasospastic compounds and method for preparing same |
| IL110376A (en) | 1993-08-02 | 1998-08-16 | Bristol Myers Squibb Co | Pharmaceutical compositions containing ifetroban salts and methods for the preparation thereof |
| US5506248A (en) | 1993-08-02 | 1996-04-09 | Bristol-Myers Squibb Company | Pharmaceutical compositions having good dissolution properties |
| US6509348B1 (en) | 1998-11-03 | 2003-01-21 | Bristol-Myers Squibb Company | Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination |
| US20030040534A1 (en) * | 2001-04-16 | 2003-02-27 | Hughes David E. | Enantiomers of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide |
| US20050020657A1 (en) * | 2002-07-09 | 2005-01-27 | B.M.R.A. Corporation B.V. | Compositions and methods involving the combination of a thromboxane A2 receptor antagonist and an inhibitor of cyclooxygenase-2 |
| US20060009496A1 (en) | 2004-06-15 | 2006-01-12 | Oates John A | Method for preventing hemoprotein and heme-mediated lipid peroxidation |
| WO2006066008A2 (en) | 2004-12-14 | 2006-06-22 | Portola Pharmaceuticals, Inc. | Device and methods for identifying and treating aspirin non-responsive patients |
| US7411071B2 (en) | 2005-01-13 | 2008-08-12 | Bristol-Myers Squibb Company | Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| US8796286B2 (en) | 2005-06-10 | 2014-08-05 | Mezzion Pharma Co., Ltd. | Agent for treatment of liver diseases containing pyrazolopyrimidinone derivative |
| US20090022729A1 (en) | 2007-04-13 | 2009-01-22 | Nigel Mackman | Methods and compositions for treating cardiac dysfunctions |
| US20090012136A1 (en) | 2007-05-03 | 2009-01-08 | Portola Pharmaceuticals, Inc. | Unit dose formulations and methods of treating and preventing thrombosis with thromboxane receptor antagonists |
| US8299097B2 (en) | 2008-09-12 | 2012-10-30 | The Brigham And Women's Hospital, Inc. | Methods for treating inflammatory disorders |
| JP2013532635A (ja) | 2010-07-14 | 2013-08-19 | カンバーランド エマージング テクノロジーズ，インコーポレーテッド | トロンボキサン−ａ２受容体アンタゴニストでの肝腎症候群および肝性脳症の治療方法 |
| US20140080154A1 (en) | 2011-04-15 | 2014-03-20 | Vivabiocell S.P.A. | Immunodiagnostic method for diagnosing auto-immune systemic sclerosis (ssc) and systemic lupus erythematosus (sle) |
| ES2699226T3 (es) * | 2011-10-14 | 2019-02-08 | Bristol Myers Squibb Co | Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor XIa |
| CN111728970A (zh) | 2014-05-16 | 2020-10-02 | 坎伯兰医药品股份有限公司 | 用伊非曲班治疗心脏纤维化的组合物和方法 |
| EP3316882A4 (en) | 2015-06-30 | 2019-02-20 | Cumberland Pharmaceuticals Inc. | ANTAGONISTS OF THROMBOXANE RECEPTOR IN MREA / ASTHMA |
| CN115624549A (zh) | 2016-05-11 | 2023-01-20 | 坎伯兰医药品股份有限公司 | 用血栓烷-a2受体拮抗剂治疗肌营养不良的组合物和方法 |
| US20180050020A1 (en) | 2016-08-22 | 2018-02-22 | Cumberland Pharmaceuticals, Inc. | Ifetroban treatment of portal hypertension |
-
2015
- 2015-05-18 CN CN202010669751.8A patent/CN111728970A/zh active Pending
- 2015-05-18 ES ES15792047T patent/ES2848348T3/es active Active
- 2015-05-18 US US14/715,143 patent/US9693998B2/en active Active
- 2015-05-18 AU AU2015258805A patent/AU2015258805B2/en active Active
- 2015-05-18 DK DK15792047.1T patent/DK3142655T3/da active
- 2015-05-18 JP JP2017512891A patent/JP6273072B2/ja active Active
- 2015-05-18 WO PCT/US2015/031395 patent/WO2015176060A1/en not_active Ceased
- 2015-05-18 EP EP20209322.5A patent/EP3804717A1/en active Pending
- 2015-05-18 CN CN201580036251.8A patent/CN107072972B/zh active Active
- 2015-05-18 EP EP15792047.1A patent/EP3142655B1/en active Active
-
2016
- 2016-11-15 ZA ZA2016/07878A patent/ZA201607878B/en unknown
-
2017
- 2017-05-30 US US15/608,507 patent/US10016399B2/en active Active
-
2018
- 2018-06-11 US US16/004,666 patent/US10314824B2/en active Active
- 2018-08-10 AU AU2018214135A patent/AU2018214135B2/en active Active
-
2019
- 2019-04-23 US US16/391,444 patent/US10583126B2/en active Active
-
2020
- 2020-01-27 US US16/752,933 patent/US10925860B2/en active Active
-
2021
- 2021-01-17 US US17/151,181 patent/US20210137895A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015258805A1 (en) | 2016-12-01 |
| JP6273072B2 (ja) | 2018-01-31 |
| EP3142655A1 (en) | 2017-03-22 |
| EP3142655B1 (en) | 2020-12-02 |
| US10016399B2 (en) | 2018-07-10 |
| EP3804717A1 (en) | 2021-04-14 |
| US9693998B2 (en) | 2017-07-04 |
| CN107072972A (zh) | 2017-08-18 |
| CN111728970A (zh) | 2020-10-02 |
| EP3142655A4 (en) | 2017-12-20 |
| US20150328190A1 (en) | 2015-11-19 |
| US20210137895A1 (en) | 2021-05-13 |
| AU2015258805B2 (en) | 2018-05-10 |
| JP2017522363A (ja) | 2017-08-10 |
| US20170258771A1 (en) | 2017-09-14 |
| AU2018214135B2 (en) | 2020-04-16 |
| WO2015176060A1 (en) | 2015-11-19 |
| CN107072972B (zh) | 2020-08-04 |
| AU2018214135A1 (en) | 2018-08-30 |
| US10583126B2 (en) | 2020-03-10 |
| US10314824B2 (en) | 2019-06-11 |
| US10925860B2 (en) | 2021-02-23 |
| ES2848348T3 (es) | 2021-08-06 |
| US20190247364A1 (en) | 2019-08-15 |
| US20200155512A1 (en) | 2020-05-21 |
| US20180344704A1 (en) | 2018-12-06 |
| ZA201607878B (en) | 2019-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3102673T3 (da) | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi | |
| DK3212226T3 (da) | Sammensætninger og anvendelsesfremgangsmåder til behandling af metaboliske lidelser | |
| DK3234133T3 (da) | Crispr-baserede sammensætninger og fremgangsmåder til anvendelse | |
| DK3317284T3 (da) | Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse | |
| DK3386484T3 (da) | Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler | |
| DK3144001T3 (da) | Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf | |
| DK3206497T3 (da) | Sammensætninger og fremgangsmåder til behandling af meibomsk kirtel-dysfunktion | |
| PL3277270T3 (pl) | Kompozycje i sposoby leczenia niedokrwistości | |
| DK3212778T3 (da) | Fremgangsmåder og sammensætninger til stabilisering af trans-splejsning af intein-modificerede proteaser | |
| DK3548033T3 (da) | Forbindelser og deres fremgangsmåde til anvendelse | |
| DK3394065T3 (da) | Tetrahydropyranyl-amino-pyrrolopyrimidinon og fremgangsmåder til anvendelse deraf | |
| DK3185868T3 (da) | Hidtil ukendte ULK1-inhibitorer og fremgangsmåder til anvendelse af samme | |
| DK3557998T3 (da) | Sammensætninger, kompositioner og anvendelsesmetoder | |
| DK3204497T3 (da) | Terapeutisk hæmning af lactatdehydrogenase og midler dertil | |
| DK3189074T3 (da) | Sammensætninger og metoder til behandling og forebyggelse af inflammation | |
| DK3209696T3 (da) | Fremgangsmåder og sammensætninger til diagnosticering og behandling af glioblastom | |
| DK3089971T3 (da) | Forbindelser og fremgangsmåder til anvendelse | |
| DK3261644T3 (da) | Sammensætninger og fremgangsmåder til behandling af nethindenedbrydning | |
| DK3242947T3 (da) | Genterapi og elektroporese til behandling af maligniteter | |
| DK3194564T3 (da) | Trichodermasammensætninger og anvendelsesfremgangsmåder | |
| DK3331879T3 (da) | Benzazolforbindelser og fremgangsmåder til fremstilling og anvendelse af forbindelserne | |
| DK3393655T3 (da) | Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme | |
| DK3142664T3 (da) | Sammensætninger og fremgangsmåder til behandling og diagnosticering af øjensygdomme | |
| DK3288379T3 (da) | Peptidsammensætninger og anvendelsesmåder | |
| DK3142655T3 (da) | Sammensætninger og fremgangsmåder til behandling af hjertefibrose med ifetroban |